Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

Medication Treatments

News
Boston Medical Center Practitioners Develop Addiction Toolkit for Nurses
10/22/2021
Practitioners at Boston Medical Center’s Office-Based Addiction Treatment (OBAT) Training and Technical Assistance program have published a comprehensive toolkit outlining the framework and clinical skills needed to educate, train, and...
Practitioners at Boston Medical Center’s Office-Based Addiction Treatment (OBAT) Training and Technical Assistance program have published a comprehensive toolkit outlining the framework and clinical skills needed to educate, train, and...
Practitioners at Boston Medical...
10/22/2021
Addiction Professional
News
FDA Approves Higher-Dose Injectable Naloxone Product
10/20/2021
Adamis Pharmaceuticals Corp. announced on Monday that FDA has approved its high-dose (5 mg/0.5 mL) naloxone injection product to treat opioid overdose.
Adamis Pharmaceuticals Corp. announced on Monday that FDA has approved its high-dose (5 mg/0.5 mL) naloxone injection product to treat opioid overdose.
Adamis Pharmaceuticals Corp....
10/20/2021
Addiction Professional
News
Self-Reported Buprenorphine Misuse Continues Declining
10/19/2021
Newly published research from the National Institute on Drug Abuse shows that misuse of buprenorphine continues to drop even as the number of patients receiving the medication to treat opioid use disorder continues to rise.
Newly published research from the National Institute on Drug Abuse shows that misuse of buprenorphine continues to drop even as the number of patients receiving the medication to treat opioid use disorder continues to rise.
Newly published research from...
10/19/2021
Addiction Professional
News
WCSAD | Focus on Patients’ Unique Needs When Re-Conceptualizing Relapse Prevention
10/03/2021
Montare Behavioral Health CEO JD Kalmenson and Regional Director of Clinical Services Tiffany Dzioba, PsyD, LMFT, shared strategies for reconceptualizing relapse prevention during the West Coast Symposium on Addictive Disorders.
Montare Behavioral Health CEO JD Kalmenson and Regional Director of Clinical Services Tiffany Dzioba, PsyD, LMFT, shared strategies for reconceptualizing relapse prevention during the West Coast Symposium on Addictive Disorders.
Montare Behavioral Health CEO JD...
10/03/2021
Addiction Professional
News
DemeRx Begins Dosing Subjects in Study of Ibogaine for OUD
09/24/2021
DemeRx, a Miami-based atai Life Sciences platform company that is developing ibogaine for the treatment of opioid use disorder, announced that the first subjects have been dosed in its Phase 1/2a clinical trial of ibogaine HCl (DMX-1002), an...
DemeRx, a Miami-based atai Life Sciences platform company that is developing ibogaine for the treatment of opioid use disorder, announced that the first subjects have been dosed in its Phase 1/2a clinical trial of ibogaine HCl (DMX-1002), an...
DemeRx, a Miami-based atai Life...
09/24/2021
Psych Congress Network
Jon Mordis, PharmD
Perspectives
Effective Grant Management Increases Access to MAT
09/21/2021
Programs that create and manage customized formularies for not-for-profit treatment centers are helping to provide patients with medication-assisted treatment at reduced, consistent prices.
Programs that create and manage customized formularies for not-for-profit treatment centers are helping to provide patients with medication-assisted treatment at reduced, consistent prices.
Programs that create and manage...
09/21/2021
Addiction Professional
News
Buprenorphine Drastically Reduces Nonprescribed Substance Use Among Patients
09/17/2021
A study of patients who were prescribed buprenorphine for the treatment of opioid use disorder found that those whose who tested negative for the medication in urine drug tests were 10 times more likely to test positive for heroin and 7 times...
A study of patients who were prescribed buprenorphine for the treatment of opioid use disorder found that those whose who tested negative for the medication in urine drug tests were 10 times more likely to test positive for heroin and 7 times...
A study of patients who were...
09/17/2021
Addiction Professional
News
ASAM Launches Free Buprenorphine Training Module
09/13/2021
The American Society of Addiction Medicine has unveiled a free 1-hour training module for medical professionals and students on prescribing buprenorphine to patients with opioid use disorder.
The American Society of Addiction Medicine has unveiled a free 1-hour training module for medical professionals and students on prescribing buprenorphine to patients with opioid use disorder.
The American Society of...
09/13/2021
Addiction Professional
News
CCSAD | OUD Medications Offer Different Benefits, Drawbacks
09/10/2021
In a presentation Friday at the Cape Cod Symposium on Addictive Disorders, Jake Nichols, PharmD, MBA, a pharmacist in long-term recovery, discussed factors that help identify the right FDA-approved medication for different OUD patients.
In a presentation Friday at the Cape Cod Symposium on Addictive Disorders, Jake Nichols, PharmD, MBA, a pharmacist in long-term recovery, discussed factors that help identify the right FDA-approved medication for different OUD patients.
In a presentation Friday at the...
09/10/2021
Addiction Professional
News
Mydecine, Top Johns Hopkins Researcher Partner on Study of Psilocybin-Assisted Therapy for Smoking Cessation
09/10/2021
Biopharmaceutical firm Mydecine Innovations Group announced this week that it has partnered with Matthew Johnson, PhD, on a study to evaluate the use of Mydecine’s MYCO-001 compound as part of a smoking cessation program for individuals...
Biopharmaceutical firm Mydecine Innovations Group announced this week that it has partnered with Matthew Johnson, PhD, on a study to evaluate the use of Mydecine’s MYCO-001 compound as part of a smoking cessation program for individuals...
Biopharmaceutical firm Mydecine...
09/10/2021
Psych Congress Network

Advertisement

Advertisement

Browse Our Other Brands

Psych NP Institute

 

Psych Congress Network

 

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement